tradingkey.logo

Mereo BioPharma Group PLC

MREO

1.690USD

-1.250-42.52%
Close 07/10, 16:00ETQuotes delayed by 15 min
1.34BMarket Cap
LossP/E TTM

Mereo BioPharma Group PLC

1.690

-1.250-42.52%
More Details of Mereo BioPharma Group PLC Company
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
Company Info
Ticker SymbolMREO
Company nameMereo BioPharma Group PLC
IPO dateJun 09, 2016
Founded at2015
CEODr. Denise V. Scots-Knight, Ph.D.
Number of employees36
Security typeDepository Receipt
Fiscal year-endJun 09
AddressOne Cavendish Place
CityLONDON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited Kingdom
Postal codeW1G0QF
Phone443330237300
Websitehttps://www.mereobiopharma.com/
Ticker SymbolMREO
IPO dateJun 09, 2016
Founded at2015
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Alexandra (Wills) Hughes-Wilson
Ms. Alexandra (Wills) Hughes-Wilson
Chief Patient Access and Commercial Planning
Chief Patient Access and Commercial Planning
94.77K
+174.32%
Dr. John A. Lewicki, Ph.D.
Dr. John A. Lewicki, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
78.63K
+61.20%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
25.05K
--
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
12.55K
--
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Justin Roberts
Mr. Justin Roberts
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Charles E. Sermon
Mr. Charles E. Sermon
General Counsel and Business Development, Company Secretary
General Counsel and Business Development, Company Secretary
--
--
Dr. Anders Ekblom, M.D., Ph.D.
Dr. Anders Ekblom, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Christine Fox
Ms. Christine Fox
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Alexandra (Wills) Hughes-Wilson
Ms. Alexandra (Wills) Hughes-Wilson
Chief Patient Access and Commercial Planning
Chief Patient Access and Commercial Planning
94.77K
+174.32%
Dr. John A. Lewicki, Ph.D.
Dr. John A. Lewicki, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
78.63K
+61.20%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
25.05K
--
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
12.55K
--
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Justin Roberts
Mr. Justin Roberts
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Jun 14
Updated: Sat, Jun 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
14.30%
Rubric Capital Management LP
9.63%
Northpond Ventures, LLC
6.86%
Mangrove Partners
5.43%
Frazier Life Sciences Management, L.P.
5.08%
Other
58.71%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
14.30%
Rubric Capital Management LP
9.63%
Northpond Ventures, LLC
6.86%
Mangrove Partners
5.43%
Frazier Life Sciences Management, L.P.
5.08%
Other
58.71%
Shareholder Types
Shareholders
Proportion
Hedge Fund
36.01%
Investment Advisor/Hedge Fund
19.61%
Venture Capital
6.86%
Private Equity
5.63%
Investment Advisor
5.13%
Research Firm
3.10%
Individual Investor
0.86%
Bank and Trust
0.23%
Other
22.57%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
167
123.11M
77.43%
-2.93M
2025Q1
176
112.84M
70.99%
-23.15M
2024Q4
174
116.69M
75.21%
-16.90M
2024Q3
167
107.29M
69.42%
-17.56M
2024Q2
164
101.82M
66.22%
-5.20M
2024Q1
162
84.96M
60.56%
-41.79M
2023Q4
143
78.69M
56.11%
-37.03M
2023Q3
141
72.18M
51.57%
-33.53M
2023Q2
149
64.87M
50.46%
-34.19M
2023Q1
152
61.46M
49.21%
-39.78M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
22.74M
14.3%
+5.61M
+32.78%
Mar 31, 2025
Rubric Capital Management LP
15.31M
9.63%
--
--
Mar 31, 2025
Northpond Ventures, LLC
10.90M
6.86%
+10.90M
--
Jun 04, 2025
Mangrove Partners
8.64M
5.43%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
8.07M
5.08%
+250.00K
+3.20%
Apr 01, 2025
Deerfield Management Company, L.P.
6.71M
4.22%
--
--
Mar 31, 2025
Rock Springs Capital Management LP
6.68M
4.2%
-2.91M
-30.37%
Mar 31, 2025
Alkeon Capital Management LLC
4.70M
2.95%
--
--
Mar 31, 2025
683 Capital Management LLC
4.63M
2.92%
+85.00K
+1.87%
Mar 31, 2025
Clearline Capital LP
3.22M
2.02%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
iShares Genomics Immunology and Healthcare ETF
0.88%
Tema Oncology ETF
0.47%
Tema Heart & Health ETF
0.45%
SPDR S&P International Small Cap ETF
0.02%
ActivePassive International Equity ETF
0%
Formidable ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.91%
iShares Genomics Immunology and Healthcare ETF
Proportion0.88%
Tema Oncology ETF
Proportion0.47%
Tema Heart & Health ETF
Proportion0.45%
SPDR S&P International Small Cap ETF
Proportion0.02%
ActivePassive International Equity ETF
Proportion0%
Formidable ETF
Proportion0%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI